Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

Janssen’s Sirturo wins backing for conditional EU licence

CHMP recommends first-in-class multidrug-resistant tuberculosis treatment

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

Police to probe Novo Nordisk over disclosure delay

Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg

- PMLiVE

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

- PMLiVE

European Court may yet force AbbVie and InterMune to release data

Orders rethink on EMA's Humira and Esbriet injunction

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

Roche - Basel

Roche signs $1bn-plus cancer deal with Molecular Partners

Partnership could create new type of drug conjugate similar to ADCs

Janssen’s UK head moves to China

Cesar Rodriguez appointed managing director of Xian Janssen

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links